Brokerages expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to announce ($0.01) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for AVEO Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.04) and the highest estimate coming in at $0.08. AVEO Pharmaceuticals reported earnings of ($0.05) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 80%. The business is expected to issue its next earnings results on Friday, November 8th.

On average, analysts expect that AVEO Pharmaceuticals will report full year earnings of ($0.11) per share for the current financial year, with EPS estimates ranging from ($0.17) to ($0.04). For the next year, analysts anticipate that the firm will post earnings of ($0.15) per share, with EPS estimates ranging from ($0.21) to ($0.10). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.04. AVEO Pharmaceuticals had a negative net margin of 46.69% and a negative return on equity of 37.43%. The business had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $1.78 million.

Separately, Zacks Investment Research cut shares of AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 15th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. AVEO Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $1.96.

AVEO stock traded down $0.02 during midday trading on Friday, reaching $0.65. 1,737,321 shares of the company’s stock traded hands, compared to its average volume of 2,834,944. The firm has a 50-day moving average price of $0.69. AVEO Pharmaceuticals has a 52 week low of $0.49 and a 52 week high of $3.59. The stock has a market capitalization of $108.32 million, a price-to-earnings ratio of -3.42 and a beta of 0.78.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. HCR Wealth Advisors purchased a new position in shares of AVEO Pharmaceuticals during the 1st quarter valued at $28,000. Excalibur Management Corp grew its position in shares of AVEO Pharmaceuticals by 363.6% during the 1st quarter. Excalibur Management Corp now owns 51,000 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 40,000 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of AVEO Pharmaceuticals during the 1st quarter valued at $50,000. WealthTrust Axiom LLC grew its position in shares of AVEO Pharmaceuticals by 390.5% during the 1st quarter. WealthTrust Axiom LLC now owns 138,505 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 110,270 shares in the last quarter. Finally, Virtu Financial LLC grew its position in shares of AVEO Pharmaceuticals by 105.5% during the 1st quarter. Virtu Financial LLC now owns 139,585 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 71,667 shares in the last quarter. Hedge funds and other institutional investors own 28.27% of the company’s stock.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Article: Futures Contract

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.